Company intelligence / Profile preview
Imnewrun Biosciences, Inc.
Suwon, Gyeonggi-do, South Koreaimnewrun.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Imnewrun Biosciences is developing a first-in-class BBB-permeable anti–PD-L1 antibody for Alzheimer’s disease. Their lead candidate INR301 aims to restore brain immune homeostasis by modulating astrocyte–microglia–neuron communication. Other programs are at the discovery or preclinical stage targeting neurodegenerative diseases.
- Therapeutic areas
- Neurology
- Modalities
- AntibodyMonoclonal antibodyOligonucleotide
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Imnewrun Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imnewrun Biosciences, Inc..